11/8
08:46 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $41.00 price target on the stock.
Low
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $41.00 price target on the stock.
11/8
04:50 am
rnac
Rating for RNAC
Medium
Report
Rating for RNAC
11/8
04:50 am
rnac
Rating for RNAC
Medium
Report
Rating for RNAC
10/16
08:31 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $41.00 price target on the stock.
Medium
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $41.00 price target on the stock.
10/16
06:44 am
rnac
Rating for RNAC
Medium
Report
Rating for RNAC
10/16
06:44 am
rnac
Rating for RNAC
Medium
Report
Rating for RNAC
9/13
08:02 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
Medium
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
9/4
08:06 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
Low
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.